Health
Oral blood thinners cut clinical event risks in intermediate-risk atrial fibrillation study
Direct oral anticoagulants reduced serious clinical events without raising major bleeding, ScienceDaily reports.
The short version
- Researchers evaluated 1,803 atrial fibrillation patients at intermediate stroke risk in the randomized SINGLE-AF trial.[ScienceDaily]
- Patients taking direct oral anticoagulants experienced a 69% reduction in serious clinical events compared to those without anticoagulation.[ScienceDaily]
- Major bleeding rates showed no significant difference between the treated and untreated patient cohorts.[ScienceDaily]
Key facts
- The randomized SINGLE-AF trial evaluated 1,803 participants with atrial fibrillation who had an intermediate risk of stroke.[ScienceDaily]
- Serious clinical events occurred in 0.5% of DOAC-treated patients compared to 1.5% of untreated patients, reflecting a 69% risk reduction.[ScienceDaily]
- Major bleeding occurred in 0.3% of DOAC recipients and 0.5% of patients without anticoagulants, indicating no increase in bleeding risk.[ScienceDaily]
What remains uncertain
- Prior evidence from observational studies involving anticoagulants in intermediate-risk groups remains conflicting, according to the principal investigator.[ScienceDaily]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- Atrial fibrillation patients saw 69% lower risk with common blood thinnersScienceDaily - Health